Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Although immune mechanisms can suppress tumour growth, tumours establish potent, overlapping mechanisms that mediate immune evasion. Emerging evidence suggests a link between angiogenesis and the tolerance of tumours to immune mechanisms. Hypoxia, a condition that is known to drive angiogenesis in tumours, results in the release of damage-associated pattern molecules, which can trigger the rejection of tumours by the immune system. Thus, the counter-activation of tolerance mechanisms at the site of tumour hypoxia would be a crucial condition for maintaining the immunological escape of tumours. However, a direct link between tumour hypoxia and tolerance through the recruitment of regulatory cells has not been established. We proposed that tumour hypoxia induces the expression of chemotactic factors that promote tolerance. Here we show that tumour hypoxia promotes the recruitment of regulatory T (T(reg)) cells through induction of expression of the chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and angiogenesis. Thus, peripheral immune tolerance and angiogenesis programs are closely connected and cooperate to sustain tumour growth.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Hypoxia, through HIF-1α, drives the conversion of MDSCs into antigen-nonspecific suppressors of T cell function and promotes the differentiation of MDSCs into immune-suppressive TAMs, further potentiating the immune-suppressive network [80].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [80]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“For example, both HIF-1α and HIF-2α induce the production of CCL28, which promotes the recruitment of MDSCs into hepatocellular tumors, whereas HIF-1α induces production of CCL26 that enhances recruitment of Tregs into ovarian tumors (Table 1) [69, 70].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [69]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [181]
In the citing paper
“tumours secrete soluble factors, such as C-C-motif chemokine ligand 2 (CCL2), CCL28, C-X-C-motif chemokine ligand 8 (CXCL8), CXCL12, ANG2, VEGF, PlGF, and adenosine, all of which promote the recruitment of immunosuppressive cells7,17–20 (FIG. 2)”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [17]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Self-citationSummaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,887
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Self-citationImmunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Oncogenic pathway signatures in human cancers as a guide to targeted therapies
Bild, A. H., Yao, G., Chang, J. T., Wang, Q., Potti, A., Chasse, D., Joshi, M.-B., Harpole, D., Lancaster, J. M., Berchuck, A., et al. (2006) · Nature · doi:10.1038/nature04296 · Cited by 2,032
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Cited by
Items 301–400 of 1,002
Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy
Wu, J., Tang, Y., & Liang, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s172042 · Cited by 105
Brooks, J. M., de Menezes, A. N., Ibrahim, M., Archer, L., Lal, N., Bagnall, C. J., von Zeidler, S. V., Valentine, H. R., Spruce, R. J., Batis, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3314 · Cited by 125
Targeting endothelial permeability in the EPR effect
Lahooti, B., Akwii, R. G., Zahra, F. T., Sajib, M. S., Λάμπρου, Μ., Alobaida, A., Lionakis, M. S., Mattheolabakis, G., & Mikelis, C. M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.039 · Cited by 119
E3 Ubiquitin Ligase UBR5 Drives the Growth and Metastasis of Triple-Negative Breast Cancer
Liao, L., Song, M., Li, X., Tang, L., Zhang, T., Zhang, L., Pan, Y., Chouchane, L., & Ma, X. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2409 · Cited by 112
Self-citationGoedegebuure, R. S. A., de Klerk, L. K., Bass, A. J., Derks, S., & Thijssen, V. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03107 · Cited by 123
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 136
Cancer-associated adipocytes as immunomodulators in cancer
Wu, Q., Li, B., Li, J., Sun, S., Yuan, J., & Sun, S. (2021) · Biomarker Research · doi:10.1186/s40364-020-00257-6 · Cited by 105
“Tregs could also release vascular endothelial growth factor (VEGF) to facilitate neovascularization via cooperation with TGF-β [157].”
BackgroundInfluentialSox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells
Xu, Y., Dong, X., Qi, P., Ye, Y., Shen, W., Leng, L., Wang, L., Li, X., Luo, X., Chen, Y., et al. (2017) · Stem Cells · doi:10.1002/stem.2720 · Cited by 113
Self-citationGuipaud, O., Jaillet, C., Clément-Colmou, K., François, A., Supiot, S., & Milliat, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170762 · Cited by 121
Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape
Sarkar, T., Dhar, S., & Sa, G. (2021) · Current Research in Immunology · doi:10.1016/j.crimmu.2021.08.002 · Cited by 114
Liu, W.-R., Tian, M., Yang, L., Lin, Y., Jin, L., Ding, Z., Shen, Y., Peng, Y., Gao, D., Zhou, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2749 · Cited by 112
“One possible reason for this result may be related to the role of PKM2 as a transactivator for HIF, as HIF-1α was proposed to contribute to angiogenesis [39].”
Halvorsen, E. C., Hamilton, M. J., Young, A., Wadsworth, B. J., LePard, N. E., Lee, H. N., Firmino, N. S., Collier, J. L., & Bennewith, K. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1150398 · Cited by 116
“Tregs migrate to the primary tumor using chemokine receptor signaling axes such as CCL5/CCR5, CCL22/CCR4, CCL17/CCR4, CCL28/CCR10, and CXCL12/CXCR4.”
BackgroundMethodComprehensive analysis of current approaches to inhibit regulatory T cells in cancer
Pere, H., Tanchot, C., Bayry, J., Terme, M., Taieb, J., Badoual, C., Adotevi, O., Merillon, N., Marcheteau, E., Quillien, V., et al. (2012) · OncoImmunology · doi:10.4161/onci.18852 · Cited by 104
“More recently, it has been shown that intratumor Treg produce VEGF and promote angiogenesis.(24) However, Treg are not always “tumor bodyguards.”
BackgroundLiu, K., Zhang, X., Xu, W., Chen, J., Yu, J. Q., Gamble, J. R., & McCaughan, G. W. (2017) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2017.28 · Cited by 112
Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers
Katoh, M. (2019) · Clinical Science · doi:10.1042/cs20180845 · Cited by 107
Wang, Z., Gong, X., Li, J., Wang, H., Xu, X., Li, Y., Sha, X., & Zhang, Z. (2021) · ACS Nano · doi:10.1021/acsnano.1c00033 · Cited by 108
Ren, S., Xiong, X., You, H., Shen, J., & Zhou, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689132 · Cited by 114
“For example, C-C motif chemokine ligand 22 (CCL22) and C-C motif chemokine ligand 28 (CCL28) recruits Tregs into tumor (42); colony Stimulating factor 1 (CSF1), C-C motif chemokine ligand 2 (CCL2) and C-X-C motif chemokine ligand 12 (CXCL12) increases the recruitment of proinflammatory monocytes and TAMs, and convert…”
BackgroundXie, F., Liu, L.-B., Shang, W.-Q., Chang, K., Meng, Y., Mei, J., Yu, J., Li, D., & Li, M. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.04.029 · Cited by 106
DAMP-TLR-cytokine axis dictates the fate of tumor
Patidar, A., Selvaraj, S., Sarode, A. Y., Chauhan, P. S., Chattopadhyay, D., & Saha, B. (2017) · Cytokine · doi:10.1016/j.cyto.2017.10.004 · Cited by 110
The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition
Varricchi, G., Loffredo, S., Marone, G., Modestino, L., Fallahi, P., Ferrari, S. M., de Paulis, A., Antonelli, A., & Galdiero, M. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163934 · Cited by 116
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
Law, A. M. K., Lim, E., Ormandy, C. J., & Gallego‐Ortega, D. (2017) · Endocrine Related Cancer · doi:10.1530/erc-16-0404 · Cited by 120
Wang, Q., Gao, J., Di, W. J., & Wu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02576-x · Cited by 107
Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy
Ma, Z., Wang, L. Z., Cheng, J.-T., Lam, S. T., Ma, X., Xiang, X., Wong, A. L., Goh, B. C., Gong, Q., Sethi, G., et al. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7935 · Cited by 107
“In addition, in the ovarian cancer TME, HIF-1 a facilitates tumor immune tolerance and angiogenesis by driving secretion of the chemokine CCL28 and recruiting regulatory T cells to hypoxic areas (22).”
Self-citationBasic principles of tumor-associated regulatory T cell biology
Savage, P. A., Malchow, S., & Leventhal, D. S. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.08.005 · Cited by 102
Huang, Y. L., Wang, F., Wang, T., Wang, Y., Zhu, Z., Gao, Y., & Zhi, D. (2012) · Digestion · doi:10.1159/000342801 · Cited by 106
Autophagy inhibition in cancer therapy: metabolic considerations for antitumor immunity
Townsend, K. N., Hughson, L. R. K., Schlie, K., Poon, V. I., Westerback, A., & Lum, J. J. (2012) · Immunological Reviews · doi:10.1111/j.1600-065x.2012.01141.x · Cited by 102
“This response correlated with minimal survival benefit, suggesting that Tregs played a larger role in suppressing immune activity or that DCs were unable to mount a favorable immune response.”
BackgroundInfluentialKorbecki, J., Kojder, K., Barczak, K., Simińska, D., Gutowska, I., Chlubek, D., & Baranowska‐Bosiacka, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165647 · Cited by 106
“An increase in CCL28/MEC expression in a hypoxic niche also leads to the recruitment of Treg to this niche, in a process dependent on the CCR10 receptor on these cells [2,192].”
BackgroundInfluentialNanoparticles mediated tumor microenvironment modulation: current advances and applications
Raju, G. S. R., Pavitra, E., Varaprasad, G. L., Bandaru, S. S., Nagaraju, G. P., Farran, B., Huh, Y. S., & Han, Y. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01476-9 · Cited by 107
Crosstalk between angiogenesis and immune regulation in the tumor microenvironment
Kim, H. J., Ji, Y. R., & Lee, Y. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01389-z · Cited by 115
Impaired function of dendritic cells within the tumor microenvironment
Xiao, Z., Wang, R., Wang, X., Yang, H., Dong, J.-M., He, X., Yang, Y., Guo, J., Cui, J., & Zhou, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1213629 · Cited by 114
“Notably, hypoxic conditions recruit more immunosuppressive Tregs (56, 114) and TAMs (124), thereby indirectly curbing the function of DCs.”
BackgroundTumor-associated macrophages: a short compendium
Prenen, H., & Mazzone, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2997-3 · Cited by 108
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma
Wang, H.-C., Chan, L.-P., & Cho, S.-F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01084 · Cited by 99
“Treg recruitment is mediated by chemokines and associated receptors, such as CCL28-CCR10 and CXCL12-CXCR4 (36, 37).”
BackgroundThe impact of hypoxia on immune state in cancer
Mortezaee, K., & Majidpoor, J. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120057 · Cited by 106
Premetastatic soil and prevention of breast cancer brain metastasis
Liu, Y., Kosaka, A., Ikeura, M., Kohanbash, G., Fellows-Mayle, W. K., Snyder, L. A., & Okada, H. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not031 · Cited by 107
Alleviating hypoxia to improve cancer immunotherapy
Fan, P., Zhang, N., Candi, E., Agostini, M., Piacentini, M., Bernassola, F., Bove, P., Alessandro, M., Giuseppe, N., Valentina, R., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02869-2 · Cited by 105
The regulation of cancer cell migration by lung cancer cell-derived exosomes through TGF-β and IL-10
Wang, Y., YI, J., Chen, X., Zhang, Y., Xu, M. Q., & Yang, Z. (2015) · Oncology Letters · doi:10.3892/ol.2015.4044 · Cited by 107
“As angiogenesis is required for all stages of tumor growth, proangiogenic factors such as TGF-β and VEGF are required for tumor formation and development (3-6).”
Wang, J., Fang, L., Li, P., Ma, L., Na, W., Cheng, C., Gu, Y., & Deng, D. (2019) · Nano-Micro Letters · doi:10.1007/s40820-019-0305-x · Cited by 101
Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
Vela, M., Aris, M., Llorente, M., García‐Sanz, J. A., & Kremer, L. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00012 · Cited by 114
Guo, W., Zhang, C., Wang, X., Dou, D., Chen, D., & Li, J. (2022) · JCI Insight · doi:10.1172/jci.insight.152616 · Cited by 112
“stroma, or tumor-associated macrophages (TAMs) (16, 17).”
Alissafi, T., Hatzioannou, A., Legaki, A. I., Varveri, A., & Verginis, P. (2019) · Journal of Autoimmunity · doi:10.1016/j.jaut.2019.102310 · Cited by 106
Immunomodulatory Roles of VEGF Pathway Inhibitors in Renal Cell Carcinoma
Hirsch, L., Flippot, R., Escudier, B. J., & Albiges, L. K. (2020) · Drugs · doi:10.1007/s40265-020-01327-7 · Cited by 102
“Tumor hypoxia promotes the expression of CC-chemokine ligand 28 (CCL28), which recruits Treg cells in the tumor microenvironment and suppresses Teff function [52].”
BackgroundWu, P., Han, J., Gong, Y., Liu, C., Yu, H., & Xie, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101990 · Cited by 111
IL-27 in tumor immunity and immunotherapy
Murugaiyan, G., & Saha, B. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.12.002 · Cited by 99
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
“In contrast, Treg cells suppress INFγ - expressing CD4+ Th1 cells and secrete VEGF via hypoxia-induced CCL28, which both contribute to a proangiogenic tumor environment [93].”
Determinants of response and resistance to CAR T cell therapy
Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 107
Regulatory T Cells in Radiotherapeutic Responses
Schaue, D., Xie, M. W., Ratikan, J. A., & McBride, W. H. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00090 · Cited by 103
“…“dangerous” microenvironment and the extent of adaptive immunity to the tumor include the nature of the vasculature, the degree of oxidative stress, and the extent of hypoxia in a tumor (Conejo-Garcia et al., 2004; Rius et al., 2008; Sitkovsky,2009; Facciabene et al., 2011; Kandalaft et al., 2011).”
BackgroundKheshtchin, N., Arab, S., Ajami, M., Mirzaei, R., Ashourpour, M., Mousavi-Niri, N., Khosravianfar, N., Jadidi‐Niaragh, F., Namdar, A., Noorbakhsh, F., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1879-5 · Cited by 96
Carbonic anhydrase IX: A tumor acidification switch in heterogeneity and chemokine regulation
Queen, A., Bhutto, H. N., Yousuf, M., Syed, M. A., & Hassan, M. I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.01.001 · Cited by 93
Liston, A., Pasciuto, E., Fitzgerald, D. C., & Yshii, L. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00960-z · Cited by 101
“CCL2, CCL22 and CCL28 are upregulated in the tumour environment, with selective involvement of CCR4, CCR8 and CCR10 chemokine receptors for T reg cell recruitment 38–41 .”
Chemokines in tumor development and progression
Mukaida, N., & Baba, T. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.10.012 · Cited by 108
Tumour progression and metastasis
Arvelo, F. A., Sojo, F. J., & Cotte, C. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.617 · Cited by 115
Qian, C., Liu, C., Liu, W., Zhou, R., & Zhao, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1291530 · Cited by 103
Wang, W., Ma, Y., Li, J., Shi, H., Lq, W., Guo, F.-C., Zhang, J., Li, D., Mo, B.-H., Wen, F., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.19 · Cited by 97
You, Y., Li, Y., Li, M., Lei, M., Wu, M., Qu, Y., Yuan, Y., Chen, T., & Jiang, H. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.13044 · Cited by 96
Emerging roles of miR-210 and other non-coding RNAs in the hypoxic response
Huang, X., & Zuo, J. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt141 · Cited by 97
“However, tumor cells can usually utilize the hypoxic microenvironment to evade the host immune system by promoting immune tolerance and escaping immune surveillance [16,17], contributing to tumor initiation, development, and progression.”
BackgroundAlleviating tumor hypoxia with perfluorocarbon-based oxygen carriers
Krafft, M. P. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.010 · Cited by 92
Hypoxia Supports Differentiation of Terminally Exhausted CD8 T Cells
Bannoud, N., Dalotto‐Moreno, T., Kindgard, L., García, P. A., Blidner, A. G., Mariño, K. V., Rabinovich, G. A., & Croci, D. O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.660944 · Cited by 98
“These molecular pathways include the hypoxia inducible factor-1 alpha (HIF-1a)-dependent induction and recruitment of Foxp3 regulatory T cells (Tregs) through mechanisms involving TGF-b-driven STAT-3 signaling (15, 16), the release of CCL28 chemokine by tumor cells (17) and CCL22 by tumor-associated macrophages (TAMs)…”
BackgroundNanoplatform-enhanced photodynamic therapy for the induction of immunogenic cell death
Liu, X., Lu, Y., Li, X., Luo, L., & You, J. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.11.058 · Cited by 96
Rachidi, S. M., Qin, T., Sun, S., Zheng, W. J., & Li, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057911 · Cited by 87
“CCL28 Secreted by ovarian cancer cells in response to hypoxia to mediate Treg recruitment – Higher expression predicts worse survival in ovarian cancer [78] Increased CCL28 in ovarian cancer with nodal metastasis – Higher levels predict worse overall and recurrence-free survival – Consistently repressed in other cance…”
BackgroundHypoxia Reduction Sensitizes Refractory Cancers to Immunotherapy
Jayaprakash, P., Vignali, P. D. A., Delgoffe, G. M., & Curran, M. A. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-060619-022830 · Cited by 87
The role of stem cells in small-cell lung cancer: Evidence from chemoresistance to immunotherapy
Guo, W., Qiao, T., & Li, T. X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.11.006 · Cited by 95
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 99
“The work of Facciabene and colleagues invoked the role hypoxia in the recruitment of Tregs through inducing expression of chemokine CC-chemokine ligand 28 (CCL28), which in turn, promotes angiogenesis and tumor tolerance [71].”
BackgroundRegulatory T Cells in Angiogenesis
Lužnik, Z., Anchouche, S., Dana, R., & Yin, J. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000574 · Cited by 93
Liu, X., Xu, J., Zhang, B., Liu, J., Liang, C., Meng, Q., Hua, J., Yu, X., & Shi, S. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1117-9 · Cited by 83
Ni, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 89
Current perspectives on the tumor microenvironment in hepatocellular carcinoma
Santhakumar, C., Gane, E. J., Liu, K., & McCaughan, G. W. (2020) · Hepatology International · doi:10.1007/s12072-020-10104-3 · Cited by 90
“Hypoxia impairs the anti-tumor response by suppressing effector T cell responses [24], inducing regulatory T cell [25] and MDSC [26] recruitment, polarising tumor-associated macrophages (TAMs) towards an M2-like phenotype [27] and upregulating immune checkpoint molecules [24].”
BackgroundThe Complex Tumor Microenvironment in Ovarian Cancer: Therapeutic Challenges and Opportunities
Garlisi, B., Lauks, S., Aitken, C., Ogilvie, L. M., Lockington, C., Petrik, D., Eichhorn, J. S., & Petrik, J. (2024) · Current Oncology · doi:10.3390/curroncol31070283 · Cited by 100
Home Sweet Home: The Tumor Microenvironment as a Haven for Regulatory T Cells
Ondondo, B., Jones, E., Godkin, A. J., & Gallimore, A. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00197 · Cited by 103
“CCL28, a chemokine known to be upregulated by hypoxia has recently been shown to recruit CCR10 Tregs to mouse ovarian cancers (56).”
BackgroundDuan, M., Xu, Y., Li, Y., Feng, H., & Chen, Y. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03101-y · Cited by 93
“…[346]; moreover, these various facilitating effects are reflected not only by the fact that Treg cells can inhibit effector T cells but also by their active secretion of chemokines, vascular endothelial growth factor, and transforming growth factor to promote neoangiogenesis [347, 348].”
BackgroundTimperi, E., Pacella, I., Schinzari, V., Focaccetti, C., Sacco, L., Farelli, F., Caronna, R., Del Bene, G., Longo, F., Ciardi, A., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1175800 · Cited by 81
Moro, A., Mehta, R., Sahara, K., Tsilimigras, D. I., Paredes, A. Z., Farooq, A., Hyer, J. M., Endo, I., Shen, F., Guglielmi, A., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08350-8 · Cited by 88
Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment
Zhao, Y., Yu, X., & Li, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.09.014 · Cited by 84
Emerging role of RNA modification N6-methyladenosine in immune evasion
Lou, X., Wang, J.-J., Wei, Y., & Sun, J. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03585-z · Cited by 84
Wang, Y., Li, J., Nakahata, S., & Iha, H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137346 · Cited by 98
“CCL28 released by hypoxic tumor cells recruits CCR10 + Tregs, promoting tumor progression and angiogenesis [82].”
BackgroundTreg–tissue cell interactions in repair and regeneration
Loffredo, L. F., Savage, T. M., Ringham, O. R., & Arpaia, N. (2024) · The Journal of Experimental Medicine · doi:10.1084/jem.20231244 · Cited by 96
“Facciabene et al. (2011) demonstrated that tumor hypoxia leads to the recruitment of CCR10 + Treg cells, which secrete high levels of VEGF, and ablation of these Treg cells suppressed angiogenesis.”
BackgroundTumor hypoxia unveiled: insights into microenvironment, detection tools and emerging therapies
Ciepła, J., & Smolarczyk, R. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01501-1 · Cited by 94
Endurance training slows breast tumor growth in mice by suppressing Treg cells recruitment to tumors
Hagar, A., Wang, Z., 小山, 幸., Aponte-Serrano, J. O., Melo, L., Vargas, S., Carpenter, R. L., & Foley, J. (2019) · BMC Cancer · doi:10.1186/s12885-019-5745-7 · Cited by 94
Immune Cell Population in Ovarian Tumor Microenvironment
Cai, D. L., & Jin, L. (2017) · Journal of Cancer · doi:10.7150/jca.20314 · Cited by 84
“Moreover, the hypoxia milieu in ovarian tumors can promote the recruitment of Tregs by inducing the expression of CCL28, thereby advancing angiogenesis and tumor tolerance [46].”
BackgroundHistamine in cancer immunology and immunotherapy. Current status and new perspectives
Sarasola, M. D. L. P., Delgado, M. A. T., Nicoud, M. B., & Medina, V. A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.778 · Cited by 86
Immune Tumor Microenvironment in Ovarian Cancer Ascites
Almeida-Nunes, D. L., Mendes‐Frias, A., Silvestre, R., Dinis‐Oliveira, R. J., & Ricardo, S. A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810692 · Cited by 95
“, observed a high amount of Th17 cells only in the early stages of OC [129], so they decrease with the advancing stage and appear to be inversely related to Tregs [172,173].”
BackgroundA review of B7-H3 and B7-H4 immune molecules and their role in ovarian cancer
Fauci, J. M., Straughn, J. M., Ferrone, S., & Buchsbaum, D. J. (2012) · Gynecologic Oncology · doi:10.1016/j.ygyno.2012.08.017 · Cited by 83
Basal, L. A., Bailey, M. D., Romero, J., Ali, M. M., Kurenbekova, L., Yustein, J. T., Pautler, R. G., & Allen, M. J. (2017) · Chemical Science · doi:10.1039/c7sc03142d · Cited by 79
The role of regulatory T cells in the pathogenesis and treatment of prostate cancer
Karpisheh, V., Mousavi, S. M., Sheykholeslami, P. N., Fathi, M., Saray, M. M., Maleki, L. A., Jafari, R., Zolbanin, N. M., & Jadidi‐Niaragh, F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119132 · Cited by 86
Tumors vs. Chronic Wounds: An Immune Cell's Perspective
Hua, Y., & Bergers, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02178 · Cited by 89
“In contrast, Treg cells suppress INFγ -expressing CD4 Th1 cells and secrete VEGF via hypoxia-induced CCL28, that both promote an angiogenic tumor environment (104).”
BackgroundGonzález-Navajas, J. M., Fan, D. D., Yang, S., Yang, F. M., Lozano‐Ruiz, B., Shen, L., & Lee, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.625783 · Cited by 84
“The reasons for the increased intratumoral Tregs numbers over effector T cells include recruitment via different chemokines secreted by various tumor cells and other cells in the tumor microenvironment (7, 39, 40), local expansion of Tregs activated by self-antigens presented by dying tumor cells (41, 42), the ability…”
BackgroundVascular normalization in immunotherapy: A promising mechanisms combined with radiotherapy
Liu, Z., Zhao, Q., Zheng, Z., Liu, S., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111607 · Cited by 83
Yang, X. L., Liu, K. Y., Lin, F. J., Shi, H. M., & Ou, Z. L. (2017) · Oncology Reports · doi:10.3892/or.2017.5798 · Cited by 78
“They demonstrated that CCL28 production was upregulated by hypoxia, and then recruited Treg cells expressing CCR10, and ultimately promoted tumor immune tolerance and angiogenesis (15).”
BackgroundExtracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 80
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity
Matsuo, K., Yoshie, O., & Nakayama, T. (2021) · Cancers · doi:10.3390/cancers13236132 · Cited by 82
“In consistence with these findings, the infiltration of CCR10-expressing Treg cells correlates with poor clinical outcomes in these cancers (Table 1) [68,69].”
BackgroundResultMilestones in tumor vascularization and its therapeutic targeting
Palma, M. D., & Hanahan, D. (2024) · Nature Cancer · doi:10.1038/s43018-024-00780-7 · Cited by 88
Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy
Lanitis, E., Irving, M. B., & Coukos, G. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01187-w · Cited by 95
Self-citationHypoxic Microenvironment and Metastatic Bone Disease
Hiraga, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113523 · Cited by 82
“Several studies reported that hypoxia is associated with the selective accumulation of Tregs in tumors, which not only suppresses antitumor responses but also promotes angiogenesis [62].”
Lorenzo-Sanz, L., & Muñoz, P. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00232-2 · Cited by 86
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review
Larroquette, M., Domblides, C., Lefort, F., Lasserre, M., Quivy, A., Sionneau, B., Bertolaso, P., Gross‐Goupil, M., Ravaud, A., & Daste, A. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.013 · Cited by 87
Targeting type I collagen for cancer treatment
Shi, R., Zhang, Z., Zhu, A.-K., Xiong, X., Zhang, J., Xu, J., Sy, M., & Li, C. (2022) · International Journal of Cancer · doi:10.1002/ijc.33985 · Cited by 81
Lian, J., Liang, Y., Zhang, H., Lan, M., Ye, Z., Lin, B., Qiu, X., & Zeng, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912279 · Cited by 84
Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment
McRitchie, B., & Akkaya, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940052 · Cited by 83
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
Irving, M. B., de Silly, R. V., Scholten, K. B. J., Dilek, N., & Coukos, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00267 · Cited by 80
“The chemokine CCL22, for example, present in breast and prostate cancer, mediates CCR4-dependent Treg trafficking (197, 198), while hypoxia-dependent expression of the chemokine ligand CCL28 in ovarian cancer recruits Tregs via CCR10 (199), and in pancreatic cancer the upregulation of CCL5 induces the migration of CCR…”
BackgroundSelf-citationHernández-Ruíz, M., & Zlotnik, A. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2016.0076 · Cited by 83
Metadata
- Authors
- Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., & Coukos, G.
- Affiliations
- University of Pennsylvania (US)
- University of British Columbia (CA)
- Corresponding author
- Coukos, George
- ORCID
- Venue
- Nature
- Published
- 2011-07
- Volume
- 475
- Issue
- 7355
- Pages
- 226-230
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2142644858
- Cited by
- 1,376
- References
- 38
- Citations by year
- 2026: 54 · 2025: 90 · 2024: 112 · 2023: 113 · 2022: 151 · 2021: 152 · 2020: 119 · 2019: 105 · 2018: 77 · 2017: 85 · 2016: 74 · 2015: 55 · 2014: 55 · 2013: 69 · 2012: 50
- FWCI
- 26.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (R01CA116779, P01 CA 83638)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- tumor hypoxia, regulatory T cells, CCL28, chemokine recruitment, tumor angiogenesis, VEGF-A, tumor immune evasion, tumor growth, chemokines
- MeSH terms
- Animals, Female, Humans, Immune Tolerance, Mice, Inbred C57BL, Neovascularization, Pathologic, Ovarian Neoplasms, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Culture Media, Conditioned, Disease Progression, Chemokines, CC, Vascular Endothelial Growth Factor A, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, Receptors, CCR10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.